Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Tanox to Report Promising Results for AIDS Drug

October 26, 2005

The Houston-based biotechnology firm Tanox Inc. is expected today to report encouraging results from an ongoing Phase II safety and efficacy study of its intravenous HIV entry inhibitor drug TXN-355.

Designed to block entry into human cells by both X4 and R5 classes of HIV, TXN-355 lowered HIV levels in blood better than a placebo in 82 patients in the trial, with only mild adverse drug reactions reported so far, said Tanox. Patients in both control and TXN-355 groups also received a standard AIDS drug cocktail.

TXN-355 is created from the natural infection-fighting monoclonal antibodies of mice; these are genetically engineered to lose their mouse qualities and behave like human antibodies. R5 and X4 viruses use different portals to enter cells; Tanox said the dual-class blocking TXN-355 represents "a major advantage" over drugs that block HIV from infecting cells through one portal only.

Advertisement
Granted fast-track status by the Food and Drug Administration, TXN-355 could be used for a broad class of HIV patients, including those with HIV resistant to multiple drugs, said Stanley Lewis, Tanox medical director. After completion of the current trial, Tanox plans to begin a final Phase III study next year, said Lewis, adding that the drug could be on the market as early as 2009.

Back to other news for October 26, 2005

Adapted from:
Wall Street Journal
10.26.05; Marilyn Chase


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement